Re: GYN: New Blood Test for Ovarian Cancer?
From: art fougner, md (evsono@pipeline.com)
Fri Feb 15 07:02:36 2008
Baby steps, John, baby steps ... but it's worth following up.
Art
At Fri, 15 Feb 2008, Dr. John Provatopoulos B.Sc. M.D.C.M. F.R.S.C.
wrote:
>
>Here is the abstract of the paper to be published, note the cancer
>parients had already been diagnosed prior to taking the test, CA125 is
>still part of the screen, for now I just think this is heading to a much
>better way to monitor for response and reccurence than just CA125. There
>are thousands of women in the BRAC1&2 database if this screen actual
>picks up cancers in this sub group i will start getting impressed. A
>screening test always looks better and yes is more helpfull when the
>incidence of the illness in the study population is high, epidemiology
>101.
>
>>The phase II clinical trial led by Mor included 500 patients -- 350
>>healthy controls and 150 ovarian cancer patients. Mor and colleagues
>>validated the previous research -- which showed 95 percent effectiveness
>
>1: Clin Cancer Res. 2008 Feb 7
>
>Diagnostic Markers for Early Detection of Ovarian Cancer.Visintin I,
>Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A,
>Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G.
>Departments of Obstetrics and Gynecology and Reproductive Science, Yale
>University School of Medicine, New Haven, Connecticut; Division of
>Public Health Science, Fred Hutchinson Cancer Research Center, Seattle,
>Washington; The Nevada Cancer Institute, Las Vegas, Nevada; Department
>of Statistics, The George Washington University, Washington, District of
>Columbia; Millipore Corporation, Temecula, California; and Departments
>of Epidemiology and Public Health and Obstetrics and Gynecology, Yale
>Cancer Center, Yale University School of Medicine, New Haven,
>Connecticut.
>
>PURPOSE: Early detection would significantly decrease the mortality rate
>of ovarian cancer. In this study, we characterize and validate the
>combination of six serum biomarkers that discriminate between
>disease-free and ovarian cancer patients with high
>efficiency.EXPERIMENTAL DESIGN: We analyzed 362 healthy controls and 156
>newly diagnosed ovarian cancer patients. Concentrations of leptin,
>prolactin, osteopontin, insulin-like growth factor II, macrophage
>inhibitory factor, and CA-125 were determined using a multiplex,
>bead-based, immunoassay system. All six markers were evaluated in a
>training set (181 samples from the control group and 113 samples from OC
>patients) and a test set (181 sample control group and 43 ovarian
>cancer).RESULTS: Multiplex and ELISA exhibited the same pattern of
>expression for all the biomarkers. None of the biomarkers by themselves
>were good enough to differentiate healthy versus cancer cells. However,
>the combination of the six markers provided a better differentiation
>than CA-125. Four models with <2% classification error in training sets
>all had significant improvement (sensitivity 84%-98% at specificity 95%)
>over CA-125 (sensitivity 72% at specificity 95%) in the test set. The
>chosen model correctly classified 221 out of 224 specimens in the test
>set, with a classification accuracy of 98.7%.CONCLUSIONS: We describe
>the first blood biomarker test with a sensitivity of 95.3% and a
>specificity of 99.4% for the detection of ovarian cancer. Six markers
>provided a significant improvement over CA-125 alone for ovarian cancer
>detection. Validation was performed with a blinded cohort. This novel
>multiplex platform has the potential for efficient screening in patients
>who are at high risk for ovarian cancer.
>
>PMID: 18258665 [PubMed - as supplied by publisher]
>
>--
>
--
art fougner, md
"May The Wings of Liberty Never Lose a Feather." - Jack Burton
|
|
